Literature DB >> 17490399

Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma.

S Brézillon1, L Venteo, L Ramont, M-F D'Onofrio, C Perreau, M Pluot, F-X Maquart, Y Wegrowski.   

Abstract

BACKGROUND: The family of small leucine-rich proteoglycans (SLRPs), which includes decorin, lumican, biglycan and fibromodulin, constitutes an abundant component of the skin extracellular matrix. We previously demonstrated that human lumican inhibits melanoma growth and progression in a mouse experimental model, by regulating cell migration, proliferation and apoptosis. AIM: The aim of this study was to investigate the expression of lumican and decorin in human malignant melanoma and adjacent peritumoral tissue, to understand better their role in the control of growth and invasion of human melanoma.
METHODS: Expression of both proteoglycans was studied by immunohistochemistry using specific antibodies in 34 malignant melanomas, 12 Hutchinson's melanotic freckles and 4 cutaneous metastatic melanomas.
RESULTS: We showed that lumican and decorin are located in the dermis and in the peritumoral stroma of malignant melanoma, but are not found in melanoma cells or dense tumour tissue. In the healthy dermis, distant from the tumour, the increasing ratio of lumican to decorin was inversely correlated with the proliferation of the tumour cells (P = 0.035). The comparison of the level of expression of lumican protein in superficial vs. nodular subtypes of malignant melanomas showed a decrease of lumican but not decorin in the peritumoral stroma of nodular subtypes. In the peritumoral stroma, the level of expression of lumican but not decorin decreased significantly (P = 0.016) with increasing Clark levels. In addition, immunocytochemical and reverse transcription PCR analyses of malignant melanoma cell lines (A-375, HT-144) and of MRC-5 and dermal fibroblasts from healthy donors in vitro confirmed that dermal fibroblasts are responsible for lumican and decorin synthesis in skin. CONCLUSIONS. Lumican may regulate vertical progression of human malignant melanoma, but further study is necessary to clarify the antitumour mechanism and the downstream signal transduction pathways involved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17490399     DOI: 10.1111/j.1365-2230.2007.02437.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  26 in total

Review 1.  Proteoglycans in prostate cancer.

Authors:  Iris J Edwards
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

2.  Leukemia stem cells promote chemoresistance by inducing downregulation of lumican in mesenchymal stem cells.

Authors:  Zhen Yu; Lin Liu; Qiang Shu; Dong Li; Ran Wang
Journal:  Oncol Lett       Date:  2019-08-22       Impact factor: 2.967

3.  Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery.

Authors:  Xinqun Li; Mark A Truty; Ya'an Kang; Xavier Chopin-Laly; Ran Zhang; David Roife; Deyali Chatterjee; E Lin; Ryan M Thomas; Huamin Wang; Matthew H Katz; Jason B Fleming
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

Review 4.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

Review 5.  Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans.

Authors:  Renato V Iozzo; Liliana Schaefer
Journal:  FEBS J       Date:  2010-08-31       Impact factor: 5.542

6.  Lumican reduces tumor growth via induction of fas-mediated endothelial cell apoptosis.

Authors:  Kent E Williams; Logan A Fulford; Allan R Albig
Journal:  Cancer Microenviron       Date:  2010-11-18

7.  Lumican exhibits anti-angiogenic activity in a context specific manner.

Authors:  Bikram Sharma; Megan D Ramus; Christopher T Kirkwood; Emma E Sperry; Pao-Hsien Chu; Winston W Kao; Allan R Albig
Journal:  Cancer Microenviron       Date:  2013-06-18

8.  Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis.

Authors:  Anuradha Krishnan; Xia Li; Winstonwhei-Yang Kao; Kimberly Viker; Kim Butters; Howard Masuoka; Bruce Knudsen; Gregory Gores; Michael Charlton
Journal:  Lab Invest       Date:  2012-09-24       Impact factor: 5.662

9.  Lumican expression, localization and antitumor activity in prostate cancer.

Authors:  Vivien J Coulson-Thomas; Yvette M Coulson-Thomas; Tarsis F Gesteira; Claudia A Andrade de Paula; Celia R W Carneiro; Valdemar Ortiz; Leny Toma; Winston W-Y Kao; Helena B Nader
Journal:  Exp Cell Res       Date:  2013-02-08       Impact factor: 3.905

10.  The matricellular functions of small leucine-rich proteoglycans (SLRPs).

Authors:  Rosetta Merline; Roland M Schaefer; Liliana Schaefer
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.